|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We designed this study to explore the interaction of miR155HG and ANXA2 to reveal the malignancy of them in GBM development.
|
30898167 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
MIR155HG plays an important role in malignant tumors, but it is rarely reported in the occurrence and development of colorectal cancer (CRC).
|
31228357 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Chromosome 1q characterize the gynaecological malignancies, which could harbour a richness of genetic repertoire to mine for molecular markers and targets, particular gynaecologic expression profile, containing FANCI, FH and MIR155HG among others, could represent part of the transcriptomic core for diagnostic test and attractive therapeutic targets.
|
31783305 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Novel long non-coding RNAs as well as the cancer-associated ones such as SNHG5, ZFAS1, or MIR155HG were dysregulated.
|
28468592 |
2017 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.
|
27260798 |
2016 |
|
Burkitt Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed 102 prospectively collected fine needle aspirates from patients with aggressive B-NHLs in order to investigate the potential of microRNA (miR)-155, its precursor BIC, as well as miR-21 and miR-26a to differentiate BL from DLBCL, and from DLBCL/BL that include B-NHLs[11q].
|
25677902 |
2015 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
In this article, we report some novel UVs not contained in the BIC database and explore their impact in cancer predisposition based on a structural approach.
|
22144684 |
2012 |
|
Burkitt Lymphoma
|
0.060 |
AlteredExpression
|
disease |
LHGDN |
BIC is processed efficiently to microRNA-155 in Burkitt lymphoma cells.
|
18354490 |
2008 |
|
Burkitt Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In line with the results obtained with Ramos, lack of miR-155 expression after induction of BIC expression was also observed in other Burkitt lymphoma cell lines, indicating a generic and specific blockade in the processing of BIC in Burkitt lymphoma.
|
17173072 |
2007 |
|
Burkitt Lymphoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In summary, we demonstrated that expression of BIC and miR-155 is not a common finding in BL.
|
16235244 |
2006 |
|
Burkitt Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In addition, recent studies suggest the involvement of miRNAs in the initiation and progression of cancer. miR155 and BIC, its host gene, have been reported to accumulate in human B cell lymphomas, especially in diffuse large B cell lymphomas, Hodgkin lymphomas, and certain types of Burkitt lymphomas.
|
16641092 |
2006 |
|
Burkitt Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
BIC RT-PCR in the Burkitt lymphoma-derived cell line Ramos demonstrated a significant up-regulation upon cross-linking of the B-cell receptor (BcR).
|
12661002 |
2003 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
We designed this study to explore the interaction of miR155HG and ANXA2 to reveal the malignancy of them in GBM development.
|
30898167 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Novel long non-coding RNAs as well as the cancer-associated ones such as SNHG5, ZFAS1, or MIR155HG were dysregulated.
|
28468592 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.
|
27260798 |
2016 |
|
Adult Burkitt Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed 102 prospectively collected fine needle aspirates from patients with aggressive B-NHLs in order to investigate the potential of microRNA (miR)-155, its precursor BIC, as well as miR-21 and miR-26a to differentiate BL from DLBCL, and from DLBCL/BL that include B-NHLs[11q].
|
25677902 |
2015 |
|
Childhood Burkitt Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed 102 prospectively collected fine needle aspirates from patients with aggressive B-NHLs in order to investigate the potential of microRNA (miR)-155, its precursor BIC, as well as miR-21 and miR-26a to differentiate BL from DLBCL, and from DLBCL/BL that include B-NHLs[11q].
|
25677902 |
2015 |
|
Primary malignant neoplasm
|
0.040 |
GeneticVariation
|
group |
BEFREE |
In this article, we report some novel UVs not contained in the BIC database and explore their impact in cancer predisposition based on a structural approach.
|
22144684 |
2012 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In contrast, induction of BIC expression in normal tonsillar B cells resulted in very high levels of miR-155 expression and induction of BIC expression in Hodgkin's lymphoma cell lines.
|
17173072 |
2007 |
|
Adult Burkitt Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In line with the results obtained with Ramos, lack of miR-155 expression after induction of BIC expression was also observed in other Burkitt lymphoma cell lines, indicating a generic and specific blockade in the processing of BIC in Burkitt lymphoma.
|
17173072 |
2007 |
|
Childhood Burkitt Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In line with the results obtained with Ramos, lack of miR-155 expression after induction of BIC expression was also observed in other Burkitt lymphoma cell lines, indicating a generic and specific blockade in the processing of BIC in Burkitt lymphoma.
|
17173072 |
2007 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
EBV-negative and EBV latency type I BL cell lines also showed very low BIC and miR-155 expression levels as compared to HL cell lines.
|
16235244 |
2006 |
|
Adult Burkitt Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In summary, we demonstrated that expression of BIC and miR-155 is not a common finding in BL.
|
16235244 |
2006 |
|
Childhood Burkitt Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In summary, we demonstrated that expression of BIC and miR-155 is not a common finding in BL.
|
16235244 |
2006 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Most non-HL subtypes were negative for BIC as determined by RNA-ISH.
|
16041695 |
2005 |